BioLineRx to Hold Analyst and Investor Day in New York on December 4, 2012

  BioLineRx to Hold Analyst and Investor Day in New York on December 4, 2012

Business Wire

JERUSALEM -- November 12, 2012

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development
company, announced that it will host an Analyst & Investor Day on Tuesday,
December 4, 2012 in New York City beginning at 8:00 am EST.

The Company’s management team and various key opinion leaders will host a
series of presentations discussing selected compounds from BioLineRx’s
diversified portfolio.

The presentations will begin at 8:30 am EST and conclude at approximately 1:30
pm EST. A recording of the presentations will be available after the event,
through the Investor Relations section of BioLineRx’s website,
www.biolinerx.com, and at www.kcsa.com.

Analysts and qualified investors who would like to register or learn more
about the event should contact Diane Imas of KCSA Strategic Communications at
(212) 896-1242 or dimas@kcsa.com. Registration is required as space is
limited.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase I/II study; BL-1021 for
neuropathic pain is in Phase I development, BL-7040 for treating inflammatory
bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for
treating acute myeloid leukemia (AML) and other hematological cancers has
completed Phase I. In addition, BioLineRx has nine products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase III)
and commercialization. For more information on BioLineRx, please visit
www.biolinerx.com.

Contact:

KCSA Strategic Communications
Garth Russell / Todd Fromer
1 212-896-1250 / 1 212-896-1215
grussell@kcsa.com/tfromer@kcsa.com
or
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipih@netvision.net.il